Extended indication Heart failure; acute decompensated, 1st line
Therapeutic value No judgement

Product

Active substance Ularitide
Domain Cardiovascular diseases
Main indication Heart failure
Extended indication Heart failure; acute decompensated, 1st line
Manufacturer cardiorentis
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Generieken voor 1e lijn reeds beschikbaar.

Registration

Registration route Centralised (EMA)
Expected Registration 2018
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Duration of treatment Average 2 day / days
Dosage per administration 15 ng/kg/min
References Clinical trial NCT01661634
Additional remarks continue infusie

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.